Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that calculated parameters like free testosterone and bioavailable testosterone were higher in women with hirsutism and PCOS compared to controls, suggesting these might better assess hyperandrogenemia than measured hormone values.

This study concluded that albumin-bound testosterone is biologically important and significantly contributes to testosterone bioavailability in women receiving spironolactone.

This study found that salivary testosterone concentrations correlated better with hirsutism in women compared to serum testosterone measures, suggesting it may be an effective method for assessing bioavailable testosterone.

In this study, hyperandrogenemia in young women with polycystic ovary syndrome was linked to higher blood pressure, independent of factors like age, insulin resistance, obesity, or dyslipidemia.

This commentary discusses the potential use of testosterone therapy for various conditions in women and reports no new clinical results; the authors advocate for more discussion and research in this area.

This study found that serum 3 alpha-Adiol-G levels in men are significantly associated with chest hair density and acne, indicating its role in reflecting androgen activity in peripheral tissues.

In this study, women with polycystic ovary syndrome showed adverse lipoprotein profile changes that increase cardiovascular risk, which were found to be more closely related to androgen levels than body weight.

This study observed that in Namibian/Southern African men, hormone levels, particularly estradiol, influence the growth of body hair, with different effects noted in various ethnic groups.

This study assessed various androgens' diagnostic effectiveness for hyperandrogenaemia in PCOS using ROC curve analysis, but it reports no specific new results.

This study found that metformin's metabolic benefits, such as reducing fat content and improving insulin sensitivity, were less pronounced in men with early-onset androgenic alopecia compared to those with normal hair growth, possibly due to differences in systemic inflammation and vitamin D status.

This study found that women with PCOS had significantly higher hair cortisol concentrations, suggesting hyperactivation of the HPA axis may affect metabolic and inflammatory markers in those with elevated cortisol levels.

This study found that sex hormone-binding globulin promotes facial aging, while sex steroid hormones such as testosterone and estradiol inhibit it, with growth hormone levels showing no significant effect.

This study found that severity of female pattern hair loss in premenopausal women was related to other clinical signs of hyperandrogenism like hirsutism and acne, but not to biochemical measures of hyperandrogenism.

This study found that bioavailable testosterone and the free androgen index were significantly associated with various clinical and biochemical features of PCOS, including hirsutism, showing higher levels in PCOS patients compared to controls.

This review discusses how sex hormone levels and local steroid synthesis influence gender differences in aging skin, reporting no new clinical results.

Older men with lower levels of available testosterone are more likely to be frail.

This study found that the severity of female pattern hair loss in premenopausal women was associated with clinical signs of hyperandrogenism, such as hirsutism and acne, but not with biochemical parameters.

This article discusses the role of androgens in causing hirsutism and male pattern baldness in women and emphasizes the need for antiandrogen treatment to manage these conditions, without reporting new clinical results.

This study found that caucasian subjects had higher serum levels of 5 alpha-reduced androgen metabolites compared to Chinese subjects, suggesting racial differences in 5 alpha-reductase activity and a potential mechanism for increased body hair in caucasian men.

This study found no difference in male pattern baldness between patients with benign prostate hyperplasia and prostate cancer, and no correlation with serum androgen levels.

This case report describes a 48-year-old woman with a history of PCOS and chemotherapy-induced menopause who was found to have a rare ovarian steroid cell tumor causing postmenopausal hyperandrogenism.

This study examined connections between bioelements like Zn, Cu, and Mn in serum and bone tissue and hormone concentrations in men with and without erectile dysfunction, highlighting potential relationships that may help explain ED's etiology.

This review examines existing research on transdermal testosterone for treating hypoactive sexual desire disorder, suggesting it improves female sexual function with minimal side effects but highlights the need for more long-term safety data.

This study indicated that while testosterone replacement in older men with low testosterone increases muscle mass and strength and reduces fat, its effects on physical function, disability, falls, or fractures remain unclear.

This study found that testosterone replacement, with or without finasteride, did not lead to significant cognitive improvements over 36 months in healthy older men without prior cognitive impairment.

This review discusses the limitations of serum androgen measurements in diagnosing and treating women with potential androgen-related disorders and the potential role of androgen replacement therapy for those with sexual interest/arousal disorders, reporting no new results.

This study found that testosterone therapy improved physical performance and strength in older men with low testosterone over 36 months, whether administered alone or with finasteride.

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

This review discusses the safety of testosterone therapy for postmenopausal women and concludes that, aside from hirsutism and acne, it appears safe at physiological doses for several years, though more long-term studies are needed.

Randomized trials reported that testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, particularly those who had undergone oophorectomy, with reversible and well-tolerated side effects.